Very low carbohydrate (ketogenic) diets in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.

Autor: Parry-Strong A; Department of Medicine, Division of Health Sciences, University of Otago Wellington, School of Medicine and Health Sciences Building, Wellington, New Zealand., Wright-McNaughton M; Department of Medicine, Division of Health Sciences, University of Otago Wellington, School of Medicine and Health Sciences Building, Wellington, New Zealand., Weatherall M; Department of Medicine, Division of Health Sciences, University of Otago Wellington, School of Medicine and Health Sciences Building, Wellington, New Zealand., Hall RM; Department of Medicine, Division of Health Sciences, University of Otago Wellington, School of Medicine and Health Sciences Building, Wellington, New Zealand., Coppell KJ; Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Barthow C; Department of Medicine, Division of Health Sciences, University of Otago Wellington, School of Medicine and Health Sciences Building, Wellington, New Zealand., Krebs JD; Department of Medicine, Division of Health Sciences, University of Otago Wellington, School of Medicine and Health Sciences Building, Wellington, New Zealand.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Dec; Vol. 24 (12), pp. 2431-2442. Date of Electronic Publication: 2022 Sep 05.
DOI: 10.1111/dom.14837
Abstrakt: Aim: Very low carbohydrate/ketogenic diets (VLC/KDs) are popular but their role in managing pre-diabetes and type 2 diabetes (T2D) is uncertain. This study uses a systematic review and meta-analysis of randomized controlled trials to estimate the effect of these diets in this population.
Materials and Methods: A systematic review identified randomized controlled trials of at least 6 months duration comparing efficacy and safety of VLC/KDs (≤50 g carbohydrate or ≤10% total energy from carbohydrate per day) with a control diet (carbohydrate above the VLC/KD threshold) in adults with pre-diabetes or T2D. The primary outcome variable was glycated haemoglobin (HbA1c) after 12 months. The meta-analysis method was inverse variance weighting of mean values for continuous variables.
Results: Key word searches identified 2290 studies; 2221 were not in scope. A full text review of 69 studies identified eight meeting inclusion criteria; in total, it involved 606 participants. Six studies reported HbA1c (%) at 12 months; four as change from baseline with a fixed effects estimate (95% confidence interval): VLC/KD minus control of 0.01% (-0.22 to 0.25), p = .91; and two as change from baseline: -0.65% (-0.99; -0.31) [-7.1 mmol/mol (-10.8; -3.4)], p < .001. Serum triglycerides were lower with VLC/KD versus control: -0.28 mmol/L (-0.44 to -0.11), p < .001. High-density lipoprotein was higher with an estimate of 0.04 mmol/L (0.01 to 0.08), p = .03, in the five studies reporting 12-month summary data.
Conclusions: A VLC/KD may cause reductions in HbA1c and triglycerides in those with pre-diabetes or T2D but evidence of an advantage over other strategies is limited. More well-designed studies are required to provide certain evidence.
(© 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: